Amgen has an accrual ratio of -0.11 for the year to December 2024. Therefore, its statutory earnings were quite a lot less than its free cashflow. In fact, it had free cash flow of US$10b in the ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other pharmaceutical stocks. Almost no other industry goes as far as the phrase "defensive" as the ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Ron Howard, who started his career in show business playing the son of Andy Griffith's sheriff character on the 1960s sitcom, said he recently found out he and Knotts are distant cousins.

With Kelly on the staff, does it make sense for the Raiders to consider drafting OSU quarterback Will Howard? Let’s make the case for Howard as a future Raider, and why the team might want to ...

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

NASDAQ:AMGN opened at $285.42 on Monday. Amgen has a 52 week low of $253.30 and a 52 week high of $346.85. The firm has a market cap of $153.42 billion, a price-to-earnings ratio of 36.55 ...

Amgen Inc.'s Q4 2024 earnings beat expectations, with 11% YoY revenue growth and 13% EPS increase, showcasing robust performance for the company's growth strategy. Amgen's diversified portfolio ...

North Carolina Senate Leader Phil Berger sits with Amgen CEO Robert Bradway during a ceremony marking Amgen’s new drug substance production plant in Holly Springs, NC on Jan. 24, 2025.

Biopharmaceutical company Amgen (NASDAQ:AMGN) is set to announce its fourth quarter earnings results on Tuesday, February 4th, after the closing bell. Wall Street expects the company to report a 7 ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...